What is the appropriate antidote and immediate management for lignocaine (lidocaine) toxicity?

Antidote for Lidocaine (Lignocaine) Toxicity

The primary antidote for lidocaine toxicity is intravenous lipid emulsion 20%, which should be readily available wherever lidocaine is used and administered immediately upon recognition of systemic toxicity. 1

Immediate Management of Lidocaine Toxicity

Recognition of Toxicity

Lidocaine toxicity manifests in a predictable progression:

• Early CNS symptoms (occur at lower plasma concentrations): restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, drowsiness, confusion, and perioral numbness 2, 3
• Severe CNS toxicity: seizures, loss of consciousness, respiratory depression/arrest 4, 5
• Cardiovascular toxicity (occurs at higher concentrations): bradycardia, ventricular tachycardia, left axis deviation, hypotension, cardiac arrest 4, 6

Specific Antidote: Lipid Emulsion Therapy

Lipid emulsion 20% is the definitive antidote and must be immediately available wherever intravenous lidocaine is administered. 1 Staff should know its exact location for rapid access during emergencies.

Supportive Management Algorithm

1. Immediately discontinue lidocaine administration 3

2. Airway and breathing support:

   • Ensure adequate oxygenation 2
   • Intubate if respiratory depression or arrest occurs 4, 5
   • Avoid hyperventilation to prevent worsening acidosis 2

3. Seizure management:

   • Administer benzodiazepines (diazepam) as first-line anticonvulsant 3, 5
   • Continue supportive care even after seizure control 5

4. Cardiovascular support:

   • Provide chronotropic agents for bradycardia 5
   • Standard ACLS protocols for cardiac arrest 2
   • Monitor continuously as cardiotoxic effects correlate with plasma levels 5

5. Metabolic management:

   • Correct acidosis aggressively, as it potentiates toxicity 2
   • Provide hydration 2

Critical Clinical Pitfalls

Toxic symptoms can persist even after plasma lidocaine concentrations decrease below therapeutic levels, requiring prolonged monitoring and supportive care. 5 The absence of blood on aspiration does not guarantee avoidance of intravascular injection. 2

Delay in proper management of dose-related toxicity, underventilation, and altered sensitivity may lead to acidosis, cardiac arrest, and death. 2 Clinicians must maintain high vigilance for toxicity symptoms even when other explanations for clinical presentation seem plausible. 1

High-Risk Populations Requiring Extra Vigilance

• Patients with hepatic disease (impaired metabolism) 2
• Patients with cardiovascular compromise 2
• Elderly and debilitated patients 2
• Children (particularly those weighing <40 kg) 1, 6
• Patients receiving concurrent medications that prolong QT interval or affect cardiac conduction 2

Monitoring Requirements

Patients receiving intravenous lidocaine outside the operating theatre/recovery room should ideally be managed in a monitored bedspace in a high dependency unit (level 2 care), with continuous cardiovascular and respiratory monitoring. 1